乐天堂fun88

CAR-T Cells

CAR-T Cells

CAR-T therapy is an immunotherapy that uses gene engineering technologies such as viral vectors or electroporation to implant chimeric antigen receptors (CARs) that specifically recognize tumor-associated antigens and simultaneously activate T cells into the patient's T lymphocytes. These CAR-T cells are then purified and expanded in vitro before being reinfused, allowing them to inhibit and kill tumors. Shenzhen Cell Cell Technology Co., Ltd. provides R&D and outsourced production services for CAR-T cells targeting different targets. Currently, it has successfully used its self-produced industrial-grade retroviral vectors to prepare multiple CAR-T cells targeting CD19, CD38, and BCMA-CD38 dual targets, with transduction efficiencies exceeding 70%. The company can provide a complete service from T lymphocyte collection, transduction of tumor-targeting viral vectors, CAR-T cell expansion, safety testing, and release. Currently, it provides GMP-grade CAR-T cell production services to institutions such as Huazhong University of Science and Technology and Shenzhen Hospital.
Description
Overview
•  CAR-T therapy is an immunotherapy that uses gene engineering technologies such as viral vectors or electroporation to implant chimeric antigen receptors (CARs) that specifically recognize tumor-associated antigens and simultaneously activate T cells into the patient's T lymphocytes. These CAR-T cells are then purified and expanded in vitro before being reinfused, allowing them to inhibit and kill tumors. • Shenzhen Cell Cell Technology Co., Ltd. can provide R&D and outsourced production services for CAR-T cells targeting different targets . Currently, it has successfully used its self-produced industrial-grade retroviral vectors to prepare multiple CAR-T cell lines targeting CD19, CD38, and BCMA-CD38 dual targets , with transduction efficiencies exceeding 70%. It can complete the entire process from T lymphocyte collection, transduction of tumor-targeting viral vectors , CAR-T cell expansion, safety testing, and release. Currently, it provides GMP-grade CAR-T cell production services to institutions such as Huazhong University of Science and Technology Union Hospital and Shenzhen Hospital.

Production process

GMP-grade CAR-T cell industrial production process


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact：Ms. Lai

Email：laijiaqi@wfzydp.com

Address：No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书：(粤)-非经营性-2022-0426  Technical Support：YouDian Software